For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Sermorelin (GHRH 1-29) is the only compound in this research series with a history of full FDA approval, voluntarily discontinued for commercial reasons in 2008. It stimulates endogenous GH release via pituitary GHRH receptors with a built-in somatostatin safety ceiling. Human evidence includes the approved pediatric GHD indication, small but consistent adult aging body composition data, and replicated cognitive function improvements in aging and MCI from the University of Washington research program.
Sermorelin occupies a paradoxical position in this research series. It is the only compound reviewed here that was previously FDA-approved but is no longer commercially available as an approved drug -- not withdrawn for safety or efficacy failures, but discontinued in 2008 for purely commercial and manufacturing reasons by the original manufacturer (Serono Laboratories). The FDA formally confirmed in 2013 that Geref's withdrawal from the market was not for reasons of safety or effectiveness.
As of March 2026, sermorelin is prescribed exclusively off-label through compounding pharmacies. It is not on the FDA Category 2 compounding prohibition list. The legitimacy of its continued compounded use rests on its former FDA approval, its well-characterized safety record from the approved indication era, and the physiological conservatism of its mechanism (stimulating the body's own pituitary axis rather than introducing exogenous GH).
Note on study attribution: several key cognitive function and brain MRS studies in this profile used tesamorelin (the more stable GHRH analog) as a sermorelin proxy, published within the University of Washington Vitiello/Merriam GHRH research program. The mechanistic attribution to GHRH signaling is the same, but the compound differs from sermorelin itself. This is noted where relevant.
Sermorelin (also known as GHRH 1-29, sermorelin acetate, or Geref) is a 29-amino acid synthetic analogue of human growth hormone-releasing hormone (GHRH) representing the shortest fully functional fragment of native GHRH. It was approved by the FDA in 1997 for the treatment of children with growth hormone deficiency or growth failure, following its earlier 1990 approval as a diagnostic agent for GH deficiency assessment.
Sermorelin stimulates pituitary gene transcription of hGH messenger RNA, increasing pituitary reserve and thereby preserving more of the growth hormone neuroendocrine axis. This concept of pituitary recrudescence -- sermorelin actively restoring pituitary capacity rather than simply extracting existing reserve -- is the mechanism that distinguishes sermorelin most fundamentally from exogenous rhGH and from tesamorelin.
The 11 to 12 minute half-life is sermorelin's most clinically significant pharmacokinetic characteristic. This very short duration means it acts as a discrete pulse trigger rather than a sustained receptor occupier -- which, counterintuitively, is mechanistically advantageous by allowing the hypothalamic-pituitary-somatotropic axis to reset fully between doses and avoid tachyphylaxis.
Sermorelin was commercially discontinued because it could not compete with rhGH for pediatric growth failure -- the very context where its physiological ceiling is a liability. Growth-deficient children need higher doses of growth hormone than can be achieved by stimulating production of their own hormone. This failure in pediatrics is paradoxically the reason sermorelin has genuine merit for aging adults, where physiological GH restoration (not supraphysiological stimulation) is the goal.
Sermorelin [GHRH-(1-29)] impacts the hypothalamic-pituitary-somatotropic axis by binding to GHRH receptors on anterior pituitary somatotrophs. GHRH receptor activation leads to cAMP production via the Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways.
Sermorelin's effects are regulated by negative feedback through the inhibitory hormone somatostatin, making physiological overdose essentially impossible -- unlike exogenous rhGH. This interaction with somatostatin prompts the pituitary to release GH in bursts that mirror natural hormone rhythms rather than the constant levels produced by rhGH injections. Additionally, sermorelin stimulates the pituitary to enhance hGH gene transcription, thereby maintaining the growth hormone neuroendocrine axis that is the first to deteriorate with age.
The four mechanistic advantages over exogenous rhGH: (1) somatostatin negative feedback preventing supraphysiological GH exposure and making overdose physiologically impossible; (2) episodic pulsatile GH release rather than constant square-wave exposure, avoiding tachyphylaxis; (3) pituitary gene transcription stimulation that actively restores pituitary reserve rather than merely exhausting remaining capacity; (4) preserved hypothalamic-pituitary-somatotropic axis integrity.
Sermorelin additionally and uniquely stimulates FSH and LH -- an off-target gonadotropin effect not documented with tesamorelin (Gelander 1989). This may have implications for male hypogonadism management, potentially offering dual-axis support when used alongside testosterone therapy, though this signal comes from pediatric data and has not been formally investigated in adult hypogonadal men.
One hundred and ten previously untreated prepubertal GH-deficient children were treated for up to 1 year with 30 micrograms/kg GHRH-(1-29) per day subcutaneously given at bedtime. The mean height velocity for the group increased from 4.1 cm/yr at baseline to 8.0 cm/yr after 6 months and 7.2 cm/yr after 12 months of therapy. At 6 months, 74% of the children were considered to have a good response to sermorelin.
Significant increases in height velocity were sustained during 12 months of treatment, with data in a few children suggesting the effect is maintained for 36 months of continued treatment. Sermorelin induced catch-up growth in the majority of growth hormone-deficient children. However, increases in height velocity with sermorelin were less than those in children receiving once-daily subcutaneous somatropin at the same dosage.
Sermorelin's approved pediatric use is the most firmly validated application reviewed here -- backed by a multicenter trial, regulatory review, and long-term follow-up data. Nearly doubling height velocity (4.1 to 8.0 cm/yr) in GH-deficient children represents a clinically dramatic response. However, the critical limitation that ended sermorelin's commercial life is embedded in this data: direct rhGH at equivalent dosing delivered superior growth velocity, because growth-deficient children require supraphysiological GH exposure that sermorelin -- constrained by the pituitary's natural ceiling -- cannot provide. This limitation in pediatrics does not diminish the mechanism's value in aging adults, where the goal is restoration to physiological rather than supraphysiological GH levels.
False positive growth hormone responses are observed in fewer children without growth hormone deficiency after sermorelin than after other provocative tests. The combination of intravenous sermorelin and arginine is a more specific test and merits evaluation in children with growth hormone deficiency. However, normal growth hormone responses to intravenous sermorelin cannot exclude growth hormone deficiency due to a hypothalamic deficit.
Sermorelin received its first FDA approval in 1990 as a diagnostic tool -- preceding its 1997 therapeutic approval by seven years. This established sermorelin's receptor specificity and its superior signal-to-noise ratio compared to older provocative tests. The arginine co-administration protocol that emerged from sermorelin's diagnostic use continues to influence GH axis testing methodology. This application is now largely superseded by oral macimorelin (FDA-approved 2017) in clinical practice.
Corpas et al. (1992) found that sermorelin successfully reversed age-related declines in GH and IGF-1 in elderly men, raising their levels toward those of the younger group. Notably, IGF-1 levels remained elevated even two weeks after stopping sermorelin, suggesting the pituitary had been reactivated rather than simply receiving a one-time signal.
In the Khorram 1997 trial, nightly GHRH analog administration induced an acute release of GH within 10 minutes lasting for 2 hours. Compared with placebo, GHRH analog induced a significant increase in 12-hour integrated nocturnal GH levels in women (P<0.01) and men (P<0.05). Within 2 weeks, serum levels of IGF-1 and IGFBP-3 increased significantly. Treatment resulted in a significant increase in skin thickness in both genders and increased lean body mass in men only, with no other changes in body composition or bone mineral density. A significant increase in insulin sensitivity occurred in men. Quality of life assessment revealed significant improvement in general well-being and libido in men, but not in women. The only adverse side effect was transient hyperlipidemia, which resolved by end of study.
The Corpas 1992 and Khorram 1997 studies are the foundational human evidence for sermorelin's adult aging application. They are small by modern RCT standards (n less than 20 each) and primarily endocrine/biomarker-focused. However, the lean body mass gains averaging 1.26 kg in men over 16 weeks, improvements in insulin sensitivity, and skin collagen thickening are objectively measured outcomes. The sex difference is a critical finding: men responded with significantly greater anabolic changes than women, possibly due to testosterone-GH axis synergy in males. The persistent IGF-1 elevation after cessation hints at the pituitary recrudescence mechanism rather than simple transient stimulation.
A 2006 study examined the effects of six months of daily sermorelin treatment on cognitive function in 89 elderly adults. Significant improvements were found on several cognitive assessments, particularly in areas of problem-solving, psychomotor processing speed, and working memory. Tests measuring crystallized intelligence (general knowledge and vocabulary) did not change. Higher GH levels were associated with better performance IQ scores, and greater IGF-1 increases correlated with higher verbal fluency scores.
In the Baker 2012 study (tesamorelin proxy), administration of GHRH improved performance on tests of fluid intelligence (working memory, planning and organization, selective attention, and processing speed) in healthy older adults, and replicated positive cognitive effects in adults with mild cognitive impairment. After 20 weeks of GHRH administration, GABA levels were increased in all brain regions (P<0.04), NAAG levels were increased in the dorsolateral frontal cortex, and MI levels decreased in the posterior cingulate. These effects were similar in adults with MCI and older adults with normal cognitive function.
Note: the Baker 2012 and Vitiello brain MRS studies used tesamorelin rather than sermorelin, though published within the same GHRH research program. The mechanistic attribution to GHRH signaling is the same, but the compound differs, which is a methodological caveat.
The cognition evidence base for the sermorelin/GHRH program is among the most compelling human signals in this category. The University of Washington group (Vitiello, Merriam) published replicated, placebo-controlled RCTs spanning two decades showing improvements in fluid intelligence domains -- working memory, processing speed, and executive function -- in both healthy older adults and MCI patients. Improvements in fluid intelligence (the form most vulnerable to aging) are precisely the domains where pharmacological intervention would have the greatest clinical value. The brain MRS neurochemical data provides a mechanistic substrate via GABA elevation. The methodological caveat that some studies used tesamorelin as a proxy requires acknowledgment.
Sermorelin uniquely stimulated both FSH and LH release, implying a potential role in the treatment of hypogonadism via the stimulation of endogenous testosterone production. This gonadotropin stimulation effect is not documented with tesamorelin.
An important limitation: sermorelin's GH-stimulating efficacy decreases in men with high visceral adiposity -- the very population most likely to seek hormone optimization. This visceral fat-mediated attenuation of GHRH response (not seen with ghrelin-pathway GHRPs) is a meaningful practical constraint when selecting between sermorelin and combination protocols.
The 2017 Sigalos retrospective study (n=105) examined men on testosterone therapy also receiving sermorelin plus GHRP-2 plus GHRP-6 and documented IGF-1 elevation. This is a combination protocol study, not a sermorelin-specific controlled trial.
The hypogonadism and male body composition evidence base for sermorelin is the weakest of all its adult use cases in terms of prospective controlled data. The 2017 Sigalos study is retrospective, uses a combination protocol rather than sermorelin alone, and measures only IGF-1 as a surrogate endpoint. The unique FSH/LH stimulation signal is intriguing but awaits properly designed adult trial confirmation. The visceral fat limitation is a documented constraint on efficacy in the obese/metabolic syndrome population that clinicians should account for.
GH is predominantly released during deep slow-wave sleep (SWS). GHRH itself has direct sleep-promoting effects via hypothalamic mechanisms independent of pituitary GH release. The Vitiello group's research program explicitly addressed somatotropic hormones, sleep, and cognition as a triad, and their data in aging subjects suggested improvements in sleep quality as part of the GHRH treatment response. No dedicated sleep-endpoint sermorelin RCT has been published.
Sleep quality improvement is mechanistically well-grounded and consistently reported in clinical experience, but lacks a dedicated sleep-primary-endpoint RCT for sermorelin specifically. The evidence is plausible extrapolation from GH biology and GHRH-sleep science, supported by secondary observations in aging trials, but cannot be rated as independently validated.
Chang et al. demonstrated that sermorelin was most effective in high-grade gliomas, particularly in those with IDH-wildtype and 1p/19q non-codeletion status. Sermorelin may inhibit tumor cell proliferation by blocking the cell cycle. The proposed mechanism is cell cycle arrest -- sermorelin binding GHRH receptors expressed on glioma cells and triggering anti-proliferative rather than pro-proliferative signaling, a receptor context-dependent effect distinct from its pituitary action.
This is the most preliminary use case in sermorelin's profile. A retrospective bioinformatic analysis of 1,018 patients is hypothesis-generating but cannot establish causality or efficacy. No prospective clinical trial has been conducted. The finding is scientifically interesting given the dismal prognosis of recurrent IDH-wildtype high-grade glioma, but remains at the level of signal identification.
GHRH analogue. Bedtime dosing standard to align with natural GH pulsatility.
Sermorelin has validated human dosing data from the FDA-approved pediatric indication (30 micrograms/kg/day) and from adult aging research studies. The adult off-label protocols are less rigorously validated but are extrapolations from the approved-indication PK and the Khorram/Corpas aging studies. The short half-life means sustained steady-state is not achievable -- each injection produces a discrete GH pulse. Research-grade quality: HPLC purity 98% or above, mass spec confirmation of the 29-AA sequence, endotoxin below 1 EU/mg.
Sermorelin vs. tesamorelin (most direct comparison): Both are GHRH-axis compounds with the same receptor target (GHRH-R on anterior pituitary somatotrophs) and the same downstream effectors. Tesamorelin's trans-3-hexenoic acid modification extends half-life sufficiently to produce sustained VAT reduction -- the application that built its FDA approval. Sermorelin's 11 to 12 minute half-life makes it metabolically shorter-acting, a liability for sustained fat reduction but preserving the episodic pulsatile rhythm most associated with the cognitive and sleep benefits documented by the Vitiello/Merriam group. Tesamorelin superseded sermorelin in HIV lipodystrophy. Sermorelin may retain advantages in cognitive aging and HPA-axis sensitive applications.
Sermorelin vs. ipamorelin (mechanistic comparison): Sermorelin acts via GHRH-R; ipamorelin acts via GHS-R1a. They can be combined for synergistic GH stimulation via complementary pathways (the basis of the CJC-1295/ipamorelin stack, where CJC-1295 is the sermorelin analog). The key distinction: sermorelin's physiological ceiling is imposed by somatostatin axis feedback; ipamorelin's safety profile relies on its GHS-R1a selectivity avoiding ACTH/cortisol. Both have somatostatin as a downstream modulator but at different points in the axis.
Intravenous single-dose and repeated once-daily subcutaneous doses of sermorelin are well tolerated. Transient facial flushing and pain at the injection site were the most commonly reported adverse events in the approved-era clinical trials.
In the Khorram clinical trial, the only adverse event observed was transient hyperlipidemia that resolved by the end of the study. No cases of impaired glucose tolerance, diabetes, fluid retention, or joint pain were reported -- side effects more commonly associated with direct rhGH injections.
Key safety considerations: contraindication in active malignancy (IGF-1 elevation is a class concern across GH axis compounds); glucose monitoring recommended given GH's counter-regulatory effect on insulin; retinopathy surveillance appropriate in diabetic patients; pregnancy contraindicated (Category C; hydrocephaly observed in rats at high doses, same signal as tesamorelin). No carcinogenicity studies have been conducted specifically for sermorelin.
IgG antibody formation has been observed but, similar to tesamorelin, appears clinically non-consequential -- antibody-positive patients retain efficacy. The physiological ceiling imposed by somatostatin feedback means that excessive IGF-1 elevation -- the primary safety concern with exogenous rhGH -- is substantially mitigated. This built-in safety ceiling is the most important pharmacological safety advantage over direct GH replacement.
Sermorelin sits in a uniquely intermediate evidential position within this research series. It has former FDA approval (giving it a safety legitimacy that purely research-stage compounds cannot claim), a well-characterized mechanism, and the most physiologically conservative approach to GH axis stimulation -- restoring a signal the body's own axis is already designed to respond to. Its mechanism of action is the most physiologically conservative of any compound reviewed: it restores a signal the body's own axis is designed to respond to, rather than introducing a new pharmacological entity.
The most clinically significant gap is the absence of large modern RCTs powered for hard clinical endpoints in adult populations -- exactly the infrastructure tesamorelin was given through Theratechnologies' commercial development program. The cognitive function evidence (Vitiello 2006, Baker 2012 program) is among the most compelling human signals in this category, showing replicated improvements in fluid intelligence domains (working memory, processing speed) in both healthy older adults and MCI patients.
Whether a compound with sermorelin's safety profile, mechanistic rationale, and cognitive function signal could produce results comparable to tesamorelin in MASLD or cognitive aging if given equivalent investment is a genuinely open and clinically important question.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use